Epigral Limited

BSE: 543332 NSE: EPIGRAL
Epigral Limited - chemicals and materials in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
CIN L24100GJ2007PLC051717 Incorporated 11 September 2007 ROC Ahmedabad HQ Ahmedabad, Gujarat, India
Active Listed - NSE: EPIGRAL · BSE: 543332 Public Limited Company chemicals and materials
Data last updated
Market Cap
₹3,841 Cr
EPIGRAL · NSE
Share Price
₹890.25
-2.51% today
Revenue
₹2,527 Cr
FY 2025-26 · -0.9% YoY
EBITDA
₹566 Cr
Margin 22.4%
Net Profit
₹330 Cr
FY 2025-26 · -7.5% YoY
P/E (TTM)
13.8x
P/B 1.7x
ROE
16.1%
ROCE 15.5%
Debt / Equity
0.28
Interest cover 18.1x

About Epigral Limited

Data last updated:

Epigral Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the industrial chemicals segment of the chemicals and materials sector. It was incorporated on 11 September 2007 and has been in existence for over 19 years.

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24100GJ2007PLC051717. Its GSTIN is 24AAFCM2288N1Z2 (Gujarat). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 543332 and NSE: EPIGRAL.

The company has an authorised share capital of ₹573.13 Cr and a paid-up capital of ₹43.14 Cr. It is led by directors including Maulik Jayantibhai Patel (Managing Director) and Kaushal Ashishbhai Soparkar (Whole-Time Director).

Its last annual general meeting (AGM) was held on 08 June 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Ahmedabad, Gujarat.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,527.18 Cr, a decline of 0.9% compared to the previous year. For the same year it recorded a net profit of ₹329.52 Cr (net margin 13%) and EBITDA of ₹566.03 Cr (EBITDA margin 22.4%). The net worth stands at ₹2,221.43 Cr (up 16.6% YoY). Total assets are valued at ₹2,812.92 Cr (up 12.4% YoY).

The company has about 967 employees on its provident fund (EPFO) records.

The company is associated with 2 brands: Epigral and Meghmani Organics Ltd. As per MCA filings, the company has open charges of ₹1,584.75 Cr and satisfied charges of ₹2,310.5 Cr on record. Court records list 26 cases involving the company, including 17 filed by the company and 9 filed against it; 11 cases are pending. The company has 12 deals on record (6 secondary share transfers, 4 funding rounds, 1 rights issue), with disclosed funding of ₹421.21 Cr; the latest was in October 2024. Its 3 peer companies in the Chemicals industry (Industrial Chemicals), with the same principal business activity (manufacture of chemicals and chemical products) are compared by revenue, 1 larger and 2 smaller; the largest is GHCL Limited with revenue of ₹3,271.22 Cr. The company has 78 MSME Form 1 returns on record between 2019 and 2024, listing 4,561 overdue payments to 250 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website meghmanifinechem.com.

Company details

CIN L24100GJ2007PLC051717
Registration Number 051717
Incorporation Date 11 September 2007
ROC Ahmedabad
Listing Status Listed - Listed on NSE (EPIGRAL); Listed on BSE (543332)
Company Status Active
Date of Last AGM 08 June 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Epigral has one previous CIN (Corporate Identification Number): U24100GJ2007PLC051717. The current CIN is L24100GJ2007PLC051717, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24100GJ2007PLC051717Current
U24100GJ2007PLC051717Previous
Key People
Maulik Jayantibhai Patel Managing Director Kaushal Ashishbhai Soparkar Whole-Time Director Sanjay Surendra Jain Cfo

Contact details

Epigral Limited's registered office is in Ahmedabad, Gujarat. Its website is meghmanifinechem.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    meghmanifinechem.com
  • Social Media
  • Registered Address
    Epigral Tower 5th 6th & 7th Floor, B/H Safal Profitaire Corporate Road Prahladnagar, Ahmedabad, Gujarat, India – 380015
  • Industry
    Chemicals and Materials, Industrial Chemicals

To see the full contact details of Epigral Limited, buy the company report.

Comprehensive company report
Epigral Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Epigral operates two associated brands: Epigral and Meghmani Organics Ltd. Each brand links to its own profile.

BrandDescriptionWebsite
Epigral
Essential derivatives and specialty chemicals are manufactured for various industries.epigral.com
Meghmani Organics Ltd
Meghmani Organics Ltd is engaged in chemical and agrochemical manufacturing.meghmani.com

Business activity

The main business activity of Epigral is manufacturing. In detail, this covers manufacture of chemicals and chemical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing20Manufacture of chemicals and chemical products

To see the full business activity and turnover split of Epigral Limited, buy the company report.

Financials of Epigral Limited

FY 2025-26 filings available

Epigral Limited reported revenue of ₹2,527.18 Cr (down 0.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,527 Cr
-0.9% YoY
EBITDA
₹566 Cr
-20.4% YoY
Profit After Tax
₹330 Cr
-7.5% YoY
Net Worth
₹2,221 Cr
+16.6% YoY
Total Assets
₹2,813 Cr
+12.4% YoY
Total Debt
₹572 Cr
-3.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue2,5272,5501,9292,1881,551829
Revenue growth-0.9%+32.2%-11.8%+41.1%+87.2%-
EBITDA566711481689509261
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%
Profit before tax341541291522383161
Net profit330356195353253101
Net profit margin+13.0%+14.0%+10.1%+16.1%+16.3%+12.2%
EPS (₹)76.9582.9147.1485.0360.8424.27
Balance sheet
Total assets2,8132,5032,2231,9511,7221,228
Net worth2,2211,9051,3091,179937684
Total debt572593909769782542
Cash & bank5.4622.196.7915.1125.090.68
Net working capital352343139105137(8.78)
Cash flow
Cash from operations436441398626284229
Cash from investing(355)(262)(401)(437)(455)(197)
Cash from financing(94.48)(164)(7.60)(200)195(31.90)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue746705736597587607628645
Revenue growth (YoY)+27.0%+16.3%+17.3%-7.5%-6.2%-6.9%--
Other income6.484.66(0.57)5.561.748.533.673.95
EBITDA136179168103132163173183
EBITDA margin+18.2%+25.4%+22.8%+17.2%+22.5%+26.9%+27.6%+28.3%
Depreciation44.2342.9041.6942.7542.3141.5433.9532.91
Interest10.787.2215.8010.9521.8423.3711.77(0.07)
Profit before tax87.5813411054.5669.65107131154
Tax22.5034.0028.5915.4518.43(53.68)44.4449.99
Net profit65.0899.7480.9539.1151.2216186.89104
EPS (₹)15.0923.1218.769.0711.8737.2520.1424.25
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,5272,5501,9292,1881,551829611
Revenue growth-0.9%+32.2%-11.8%+41.1%+87.2%+35.7%-
EBITDA567711481689509261194
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%+31.8%
Profit before tax342540291523383161141
Net profit326352196353253101112
Net profit margin+12.9%+13.8%+10.2%+16.2%+16.3%+12.2%+18.3%
EPS (₹)77.1982.6847.1285.0460.8424.2726.95
Balance sheet
Total assets2,8132,5022,2231,9511,7221,2281,117
Net worth2,2211,9041,3091,179937684583
Total debt572593909769782542526
Cash & bank5.4622.196.7915.0625.040.680.10
Net working capital352343139105137(8.83)(24.82)
Cash flow
Cash from operations436441398626284229165
Cash from investing(355)(262)(401)(437)(455)(197)(363)
Cash from financing(94.48)(164)(7.60)(200)195(31.90)69.41
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue746705736597587607628645
Revenue growth (YoY)+27.0%+16.3%+17.3%-7.5%-6.2%-6.9%--
Other income5.824.10(0.57)5.561.748.253.403.86
Total expenses610526568494455443454463
EBITDA136179169103132163173183
EBITDA margin+18.2%+25.4%+22.9%+17.2%+22.5%+26.9%+27.6%+28.3%
Depreciation44.2342.9041.6942.7542.3141.5433.9532.91
Interest10.787.2215.8010.9521.8423.3711.77(0.07)
Profit before tax86.9213311154.6069.95107131154
Tax22.5034.0028.5915.4518.43(53.68)44.4449.99

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue746705736597587607628645
Revenue growth (YoY)+27.0%+16.3%+17.3%-7.5%-6.2%-6.9%--
Other income6.484.66(0.57)5.561.748.533.673.95
EBITDA136179168103132163173183
EBITDA margin+18.2%+25.4%+22.8%+17.2%+22.5%+26.9%+27.6%+28.3%
Depreciation44.2342.9041.6942.7542.3141.5433.9532.91
Interest10.787.2215.8010.9521.8423.3711.77(0.07)
Profit before tax87.5813411054.5669.65107131154
Tax22.5034.0028.5915.4518.43(53.68)44.4449.99
Net profit65.0899.7480.9539.1151.2216186.89104
EPS (₹)15.0923.1218.769.0711.8737.2520.1424.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue2,5272,5501,9292,1881,551829
Revenue growth-0.9%+32.2%-11.8%+41.1%+87.2%-
Other income14.9816.206.607.984.112.19
Total expenses1,9611,8391,4481,4991,041567
Employee cost11697.8181.3168.8551.9941.26
EBITDA566711481689509261
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%
Depreciation16813312410985.9173.54
Interest71.9653.2773.4965.5044.2729.11
Profit before tax341541291522383161
Tax8.7918394.8816913160.02
Net profit330356195353253101
Net profit margin+13.0%+14.0%+10.1%+16.1%+16.3%+12.2%
EPS (₹)76.9582.9147.1485.0360.8424.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital43.1443.1496.55152252252
Reserves & surplus2,1781,8611,2131,028684432
Shareholders' funds (net worth)2,2211,9051,3091,179937684
Minority interest0.000.000.000.000.000.00
Secured loans563585908766778538
Unsecured loans9.057.951.352.623.763.76
Total debt572593909769782542
Total liabilities2,8132,5032,2231,9511,7221,228
Assets
Gross block2,9742,9672,4062,3201,4751,424
Net block2,1172,2381,7671,8041,0681,102
Capital work in progress45163.89483158589126
Investments22.7698.1420.5820.550.000.00
Inventories34938826321215453.96
Sundry debtors417232179166256119
Cash & bank balances5.4622.196.7915.1125.090.68
Loans & advances56.0756.1453.4026.2411.407.81
Total current assets827699502420447181
Total current liabilities475355363315310190
Net working capital352343139105137(8.78)
Total assets2,8132,5032,2231,9511,7221,228
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash18.643.1814.2425.090.680.10
Net cash from operating activities436441398626284229
Net cash from investing activities(355)(262)(401)(437)(455)(197)
Net cash from financing activities(94.48)(164)(7.60)(200)195(31.90)
Net change in cash(13.62)15.46(11.06)(10.85)24.410.58
Closing cash5.4622.196.7915.1125.090.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-0.9%+32.2%-11.8%+41.1%+87.2%-
EBITDA growth-20.4%+47.7%-30.2%+35.2%+95.0%-
PBT growth-37.0%+86.1%-44.4%+36.3%+138.4%+9997.0%
Net income growth-7.5%+82.5%-44.7%+39.8%+150.7%-
Revenue CAGR (3Y)+4.9%+18.0%+32.5%---
EBITDA CAGR (3Y)-6.3%+11.7%+22.6%---
Profitability & leverage
Net income margin+13.1%+14.0%+10.2%+16.1%+16.3%+12.2%
Return on capital employed+15.5%+25.2%+17.5%+32.0%+29.0%+15.5%
Return on net worth+16.1%+22.7%+16.9%+39.4%+42.2%+21.3%
Debt / equity0.280.470.670.730.820.79
Long-term debt / equity0.190.290.370.470.560.50
Interest cover18.099.2120.5511.2910.4515.50
Efficiency & per share
Fixed asset turnover0.850.950.821.151.070.58
Inventory turnover6.867.838.1311.9614.9115.36
Debtors turnover7.7912.4111.1810.368.276.97
EPS (₹)76.9582.9147.1485.0360.8424.27
Dividend per share (₹)5.006.005.005.000.000.00
Book value per share (₹)514.94441.48301.83257.30174.72113.88
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue746705736597587607628645
Revenue growth (YoY)+27.0%+16.3%+17.3%-7.5%-6.2%-6.9%--
Other income5.824.10(0.57)5.561.748.253.403.86
Total expenses610526568494455443454463
EBITDA136179169103132163173183
EBITDA margin+18.2%+25.4%+22.9%+17.2%+22.5%+26.9%+27.6%+28.3%
Depreciation44.2342.9041.6942.7542.3141.5433.9532.91
Interest10.787.2215.8010.9521.8423.3711.77(0.07)
Profit before tax86.9213311154.6069.95107131154
Tax22.5034.0028.5915.4518.43(53.68)44.4449.99
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,5272,5501,9292,1881,551829611
Revenue growth-0.9%+32.2%-11.8%+41.1%+87.2%+35.7%-
Other income14.9815.216.527.984.112.192.31
Total expenses1,9601,8391,4481,4991,041567416
Employee cost11697.8181.3168.8551.9941.2632.72
EBITDA567711481689509261194
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%+31.8%
Depreciation16813312410985.9173.5444.30
Interest71.9653.2773.4965.5044.2729.1111.14
Profit before tax342540291523383161141
Tax8.7918394.8816913160.0228.99
Net profit326352196353253101112
Net profit margin+12.9%+13.8%+10.2%+16.2%+16.3%+12.2%+18.3%
EPS (₹)77.1982.6847.1285.0460.8424.2726.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital43.1443.1496.55152252252252
Reserves & surplus2,1781,8601,2131,028684432331
Shareholders' funds (net worth)2,2211,9041,3091,179937684583
Secured loans563585908766778538526
Unsecured loans9.057.951.352.623.763.760.00
Total debt572593909769782542526
Total liabilities2,8132,5022,2231,9511,7221,2281,117
Assets
Gross block2,9742,9672,4062,3201,4751,424688
Net block2,1172,2381,7671,8041,0681,102440
Capital work in progress45163.89483158589126691
Investments22.8097.1420.5720.620.050.050.00
Inventories34938826321215453.9648.40
Sundry debtors41723217916625611976.45
Cash & bank balances5.4622.196.7915.0625.040.680.10
Loans & advances56.0756.1453.4026.2411.407.817.13
Total current assets827699502419447181132
Total current liabilities475355363315310190157
Net working capital352343139105137(8.83)(24.82)
Total assets2,8132,5022,2231,9511,7221,2281,117
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash18.643.1814.1925.040.680.10129
Net cash from operating activities436441398626284229165
Net cash from investing activities(355)(262)(401)(437)(455)(197)(363)
Net cash from financing activities(94.48)(164)(7.60)(200)195(31.90)69.41
Net change in cash(13.62)15.46(11.01)(10.85)24.360.58(129)
Closing cash5.4622.196.7915.0625.040.680.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-0.9%+32.2%-11.8%+41.1%+87.2%+35.7%-
EBITDA growth-20.2%+47.7%-30.2%+35.2%+95.0%+34.6%-
PBT growth-36.7%+85.8%-44.4%+36.3%+138.4%+14.1%-41.8%
Net income growth-7.4%+79.8%-44.6%+39.8%+150.7%-9.8%-
Revenue CAGR (3Y)+4.9%+18.0%+32.5%+53.0%+29.7%+11.5%+15.9%
EBITDA CAGR (3Y)-6.3%+11.7%+22.6%+52.5%+17.8%+0.8%+10.5%
Profitability & leverage
Net income margin+13.2%+14.0%+10.2%+16.2%+16.3%+12.2%+18.4%
Return on capital employed+15.6%+25.1%+17.5%+32.0%+29.0%+16.2%+15.2%
Return on net worth+16.2%+22.6%+16.9%+39.4%+42.2%+23.9%+34.2%
Debt / equity0.280.470.670.730.810.840.85
Long-term debt / equity0.190.290.370.470.560.600.73
Interest cover18.059.2120.5511.2910.4515.507.44
Efficiency & per share
Fixed asset turnover0.850.950.821.151.070.781.03
Inventory turnover6.867.838.1311.9614.9116.1913.71
Debtors turnover7.7912.4111.1810.368.278.497.94
EPS (₹)77.1982.6847.1285.0460.8424.2726.95
Dividend per share (₹)5.006.005.005.000.000.000.00
Book value per share (₹)514.94441.24301.83257.32174.72113.8889.66

To see the full year-wise statements and ratios of Epigral Limited, buy the company report.

Board of directors and KMP of Epigral Limited

Epigral Limited currently reports 12 directors and 2 key managerial personnel. 9 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Karana Rameshbhai Patel
Also directs: Navratan Specialty Chemicals LLP, Uniworth Enterprises LLP, Meghmani Dyes and Intermediates LLP and 5 more
Director10 May 201610 Years 6 MonthsCurrent
Priyanka Vishal Chopra
Also directs: Harsha Engineers International Limited, Prava Innovate Private Limited
Director28 Feb 20251 Years 8 MonthsCurrent
Gaurang Ghanshyam TrivediCompany Secretary23 Apr 20242 Years 6 MonthsCurrent
Nirali Bhavinbhai ParikhDirector30 Mar 201511 Years 7 MonthsCurrent
Maulik Jayantibhai Patel
Also directs: Meghmani Organics Limited, Meghmani Crop Nutrition Limited, Kilburn Chemicals Limited and 5 more
Managing Director10 May 201610 Years 6 MonthsCurrent
Raju SwamyDirector20 May 20215 Years 5 MonthsCurrent
Showing 6 of 14 current directors and KMP. View all directors and KMP

Peer comparison

Epigral Limited is compared with the 3 companies closest to it by revenue in the Chemicals industry (Industrial Chemicals), with the same principal business activity (manufacture of chemicals and chemical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
GHCL Limited₹3,271.22 Cr (FY 2025)-7.0%Ahmedabad, Gujarat, India
Epigral Limitedthis company₹2,527.18 Cr (FY 2026)₹329.52 Cr13%-0.9%967Ahmedabad, Gujarat, India
Navin Fluorine International Limited₹2,393.11 Cr (FY 2025)13.0%Mumbai, Maharashtra, India
Sud Chemie India Private Limited₹2,029.17 Cr (FY 2025)-13.0%Ernakulam, Kerala, India

To see the full peer comparison of Epigral Limited, buy the company report.

Auditor

Epigral Limited is audited by S R B C & CO LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
S R B C & CO LLPFY 2025324982E/E300003

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 68.80%, foreign institutional investors hold 1.00%, domestic institutional investors hold 5.60% and retail and other public shareholders hold 24.60%.

Promoters: 68.80%DII (Domestic Institutional): 5.60%FII (Foreign Institutional): 1.00%Retail & Others: 24.60%
Sep 2026
QUARTER
68.80% Promoters
5.60% DII (Domestic Institutional)
1.00% FII (Foreign Institutional)
24.60% Retail & Others
Promoter holding - history
Now 68.80% · Sep 2026High 68.80% · Dec 2025Low 68.80% · Dec 2025
67%67.8%68.5%69.3%70%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 68.80%Mar 2026: 68.80%Jun 2026: 68.80%Sep 2026: 68.80%68.80%68.80%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters68.80%68.80%68.80%68.80%
Public31.20%31.20%31.20%31.20%

Charges & borrowings

Open charges
₹1,584.75 Cr
Satisfied charges
₹2,310.5 Cr
Breakdown by lending institutions
Axis Bank Limited₹700.00 Cr
Others₹600.00 Cr
Hdfc Bank Limited₹284.75 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
12 Jun 2024100936549Axis Bank Limited₹350 CrOpen
22 Apr 2024100918998Axis Bank Limited₹350 CrOpen
18 Jun 2021100452318Hdfc Bank Limited₹284.75 CrOpen
17 Jun 201310435255Others₹600 CrOpen
20 Feb 2021100422630State Bank of India₹190 CrSatisfied

To see the full charge records of Epigral Limited, buy the company report.

Total charge records: 20 View all charges

Deals & funding

Epigral Limited has 12 deals on record (6 secondary share transfers, 4 funding rounds, 1 rights issue), with disclosed funding of ₹421.21 Cr; the latest was in October 2024.

Total deals
12
Secondary share transfers
6
Funding rounds
4
Rights issue
1
QIP
1
Disclosed funding
₹421.21 Cr

Deals on record (5 of 12)

WhenDealAmountParties
Oct 2024QIP₹333.06 CrInvestors: Others - QIP Investors, Hsbc Focused Fund, Bandhan Small Cap Fund
Dec 2019Secondary share transferUndisclosedBuyer: an individual
Seller: an individual
Oct 2019Secondary share transferUndisclosedBuyer: an individual
Seller: an individual
Apr 2018Secondary share transferUndisclosedBuyer: Meghmani Agrochemicals Private Limited
Seller: International Finance Corporation
Oct 2017Secondary share transferUndisclosedBuyer: Meghmani Agrochemicals Private Limited
Seller: Meghmani Organics Limited

To see the full deal history of Epigral Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Epigral Limited was last rated by Crisil on 21 Oct 2020.

Rating agencyRated onRating
Crisil21 Oct 2020

To see the full credit ratings and regulatory alerts of Epigral Limited, buy the company report.

MSME payment delays

Epigral Limited has 78 MSME Form 1 returns on record between 2019 and 2024, listing 4,561 overdue payments to 250 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 250)

SupplierAmount dueDue sinceReported on
an individual supplier
Chemoil Advance Technology
an individual supplier
an individual supplier
Kitz India Private Limited

To see the full MSME payment records of Epigral Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Epigral has 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Associated companies

Employees & EPFO

Epigral Limited has a workforce of 967 employees on its EPFO records as of Dec 03, 2024, across 1 active EPFO establishment.

Employee count
967
Active EPFO establishments
1
Employee growth
4.88%

GST

Epigral has 2 GST registrations: 2 active.

Total GSTINs
2
Active
2
GSTINStateStatusRegistered on
24AAFCM2288N1Z2GujaratActive01 Jul 2017
27AAFCM2288N1ZWMaharashtraActive10 Dec 2021

To see the full GST registrations and return filing status of Epigral Limited, buy the company report.

Recent activity

Epigral Limited has 22 board changes on record since 2014: 14 appointments and 8 cessations. The latest: Priyanka Vishal Chopra was appointed as Director on 28 Feb 2025.

AGM
Epigral Limited last Annual general meeting of members was held on 08 Jun 2026 as per latest MCA records.
Filing
Epigral Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Appointed
Priyanka Vishal Chopra was appointed as Director.
Charges
A charge registered on 30 May 2019 via Charge ID 100268462 with Hdfc Bank Limited was fully satisfied on 29 Jan 2025.
Charges
A charge registered on 20 Feb 2021 via Charge ID 100422630 with State Bank Of India was fully satisfied on 02 Jan 2025.
Charges
A charge registered on 30 Nov 2020 via Charge ID 100394926 with State Bank Of India was fully satisfied on 02 Jan 2025.
Charges
A charge registered on 13 Feb 2019 via Charge ID 100237762 with Others was fully satisfied on 07 Dec 2024.
Charges
A charge registered on 19 Jan 2019 via Charge ID 100234983 with Hdfc Bank Limited was fully satisfied on 05 Dec 2024.
Charges
A charge with Axis Bank Limited amounted to Rs. 350.00 Cr with Charge ID 100936549 was registered on 12 Jun 2024.
Charges
A charge with Others of Rs. 600.00 Cr registered on 17 Jun 2013 with Charge ID 10435255 was modified on 10 Jun 2024.
Appointed
Gaurang Ghanshyam Trivedi was appointed as Company Secretary.
Charges
A charge with Axis Bank Limited amounted to Rs. 350.00 Cr with Charge ID 100918998 was registered on 22 Apr 2024.

55 earlier events are in the company report.

News

EPIGRAL: Q2 CONS NET PROFIT 651M RUPEES VS 512M (YOY)
02 Nov 2026 · Exchange Update
EPIGRAL: Q2 EBITDA 1.36B RUPEES VS 1.32B (YOY); Q2 EBITDA MARGIN 18.3% VS 22.53% (YOY)
02 Nov 2026 · Exchange Update
EPIGRAL: Q2 REVENUE 7.4B RUPEES VS 5.9B (YOY)
02 Nov 2026 · Exchange Update
Epigral: Co MD Assures Optimistic View For Second Half Of FY27.
02 Nov 2026 · Exchange Update
Epigral: Co's Cmd Says Capacity Scale-ups To Drive Co's Rs 5,000 Crore Target By Fy31
28 Sep 2026 · Exchange Update

Frequently asked questions

Epigral is an active public limited company based in Ahmedabad, Gujarat, India. The company works in industrial chemicals, within the chemicals and materials industry. It was incorporated on 11 September 2007 (19+ years old) and is registered under CIN L24100GJ2007PLC051717. Listed on BSE: 543332 and NSE: EPIGRAL.

Epigral reported revenue of ₹2,527.18 Cr for FY 2025-26 (down 0.9% YoY) based on consolidated financials.

Epigral has 14 current directors and KMP:

The latest financial statements of Epigral on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 08 June 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Epigral is 24AAFCM2288N1Z2, registered in Gujarat. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 27AAFCM2288N1ZW (Maharashtra).

The CIN (Corporate Identification Number) of Epigral is L24100GJ2007PLC051717. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Epigral is a listed company as per MCA records. Its shares are listed on both BSE (code: 543332) and NSE (symbol: EPIGRAL).

Epigral has 26 court cases on record: 17 filed by the company and 9 filed against it. 11 are pending. Most are in the high courts.

Epigral was incorporated on 11 September 2007, making it 19+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Epigral has 12 deals on record (6 secondary share transfers, 4 funding rounds, 1 rights issue), with disclosed funding of ₹421.21 Cr; the latest was in October 2024.

The peers of Epigral by revenue are GHCL Limited, Navin Fluorine International Limited, Sud Chemie India Private Limited, all in the Chemicals industry (Industrial Chemicals), with the same principal business activity (manufacture of chemicals and chemical products).

Priyanka Vishal Chopra was appointed as Director on 28 Feb 2025. Gaurang Ghanshyam Trivedi was appointed as Company Secretary on 23 Apr 2024. Kamlesh Mehta was appointed as Nodal Officer on 25 Aug 2022. Epigral has 22 board changes on record in total.